Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jim Young

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|February 20, 2025
Liver Fibrosis Regression in People Living With HIV After Successful Treatment for Hepatitis CJim Young, Shouao Wang, Rachel Sacks-Davis, et al.
CMAJ Open|December 9, 2014
The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort studyMarina B Klein, Jim Young, David Dunn, et al.
Patient Preference and Adherence|December 20, 2022
Virological Outcomes After Switching to Abacavir/Lamivudine/Dolutegravir Combined with Adherence Support in People Living with HIV with Poor Adherence: A Phase IV, Multicentre Randomized Prospective Open Label Study (TriiADD-CTN 286)Marina B Klein, Jim Young, David Ortiz-Paredes, et al.
Plos Medicine|March 27, 2012
CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE, Jim Young, Mina Psichogiou, et al.
International Journal of Epidemiology|December 9, 2023
Cohort Profile: International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC)Daniela K van Santen, Ashleigh Stewart, Joseph S Doyle, et al.
Eclinicalmedicine|January 9, 2023
Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: Findings from a multinational cohort between 2010 and 2019Daniela K van Santen, Rachel Sacks-Davis, Ashleigh Stewart, et al.
The Lancet. HIV|January 15, 2024
Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studiesRachel Sacks-Davis, Daniela K van Santen, Anders Boyd, et al.
BMJ Open|March 20, 2026
PRECISION study: impact of personalised cardiac anaesthesia and cerebral autoregulation on neurological outcomes in patients undergoing cardiac surgery - protocol for an international, multicentre, prospective cohort studyNuno V Gomes, Harry Edgar-Whelan, Erta Beqiri, et al.
AIDS (London, England)|February 19, 2025
Time to direct-acting antiviral initiation and liver-related events in people with HIV and hepatitis C virusMathieu Chalouni, Daniela K Van Santen, Juan Berenguer, et al.
AIDS (London, England)|March 25, 2026
Risk of type 2 diabetes mellitus after treatment with direct-acting antivirals for Hepatitis C virus in people with HIVMathieu Chalouni, Jessie Torgersen, Christopher T Rentsch, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Journal of Acquired Immune Deficiency Syndromes (1999)|February 20, 2025
Liver Fibrosis Regression in People Living With HIV After Successful Treatment for Hepatitis CJim Young, Shouao Wang, Rachel Sacks-Davis, et al.
CMAJ Open|December 9, 2014
The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort studyMarina B Klein, Jim Young, David Dunn, et al.
Patient Preference and Adherence|December 20, 2022
Virological Outcomes After Switching to Abacavir/Lamivudine/Dolutegravir Combined with Adherence Support in People Living with HIV with Poor Adherence: A Phase IV, Multicentre Randomized Prospective Open Label Study (TriiADD-CTN 286)Marina B Klein, Jim Young, David Ortiz-Paredes, et al.
Plos Medicine|March 27, 2012
CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE, Jim Young, Mina Psichogiou, et al.
International Journal of Epidemiology|December 9, 2023
Cohort Profile: International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC)Daniela K van Santen, Ashleigh Stewart, Joseph S Doyle, et al.
Eclinicalmedicine|January 9, 2023
Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: Findings from a multinational cohort between 2010 and 2019Daniela K van Santen, Rachel Sacks-Davis, Ashleigh Stewart, et al.
The Lancet. HIV|January 15, 2024
Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studiesRachel Sacks-Davis, Daniela K van Santen, Anders Boyd, et al.
BMJ Open|March 20, 2026
PRECISION study: impact of personalised cardiac anaesthesia and cerebral autoregulation on neurological outcomes in patients undergoing cardiac surgery - protocol for an international, multicentre, prospective cohort studyNuno V Gomes, Harry Edgar-Whelan, Erta Beqiri, et al.
AIDS (London, England)|February 19, 2025
Time to direct-acting antiviral initiation and liver-related events in people with HIV and hepatitis C virusMathieu Chalouni, Daniela K Van Santen, Juan Berenguer, et al.
AIDS (London, England)|March 25, 2026
Risk of type 2 diabetes mellitus after treatment with direct-acting antivirals for Hepatitis C virus in people with HIVMathieu Chalouni, Jessie Torgersen, Christopher T Rentsch, et al.
Pageof 8